2007 full-year growth was 16%, driven by the strength of the sublingual route desensitisation segment (SLIT), which grew 21%. The significant increase in the number of new patients, in particular in France and Germany, and growing sales excluding subsidiaries were the main growth drivers.
2007 results, should exceed those of 2006 (EBIT of EUR 23 million), in spite of a further significant increase in R&D expenses.
2008 outlook
The Group gives guidance of double-digit sales growth. 2008 results should be impacted by additional R&D investments in the US.
The questions asked by the German agency regarding the ORALAIR(R) Grasses file have been dealt with and we expect a licence to be issued.
Talks are continuing with potential partners in the US.
About STALLERGENES
Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis, rhinitis and allergic asthma.
A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.
StallergEnes realised 2007 sales of EUR 147 million, of which half outside France.
StallergEnes’ shares are listed on Compartment B of the Euronext Paris Stock Exchange.
ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP
For additional information on StallergEnes, please visit our website: http://www.stallergenes.com
CONTACT: PAVIE FINANCE: Albert SAPORTA- Chairman/ Christian THIRY - Chief
Financial Officer, Tel: +33(0)1-55-59-20-95,
investorrelations@stallergenes.fr; Lucile de FRAGUIER, Analyst-investor
Relations, Tel: +33(0)1-42-15-04-39, contact@pavie-finance.com
